The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Venetoclax in AML updates: approval & combinations
The FDA recently approved venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed adult acute myeloid leukemia (AML). Here, Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, presents the results of the Phase II study of venetoclax with 10-day decitabine (NCT03404193), as well as an ongoing study of venetoclax plus the MDM2 inhibitor idasanutlin. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
